Limosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications

Zichen Luo; Ailing Chen; Anni Xie; Xueying Liu; Shanyu Jiang; Renqiang Yu

doi:10.3389/fimmu.2023.1228754

Limosilactobacillus reuteri in immunomodulation: molecular mechanisms and potential applications

Front Immunol. 2023 Aug 9:14:1228754. doi: 10.3389/fimmu.2023.1228754. eCollection 2023.

Authors

Zichen Luo¹, Ailing Chen², Anni Xie¹, Xueying Liu², Shanyu Jiang¹, Renqiang Yu^{1

2}

Affiliations

¹ Department of Neonatology, Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China.
² Research Institute for Reproductive Health and Genetic Diseases, Women's Hospital of Jiangnan University, Wuxi Maternity and Child Health Care Hospital, Wuxi, China.

Abstract

Frequent use of hormones and drugs may be associated with side-effects. Recent studies have shown that probiotics have effects on the prevention and treatment of immune-related diseases. Limosilactobacillus reuteri (L. reuteri) had regulatory effects on intestinal microbiota, host epithelial cells, immune cells, cytokines, antibodies (Ab), toll-like receptors (TLRs), tryptophan (Try) metabolism, antioxidant enzymes, and expression of related genes, and exhibits antibacterial and anti-inflammatory effects, leading to alleviation of disease symptoms. Although the specific composition of the cell-free supernatant (CFS) of L. reuteri has not been clarified, its efficacy in animal models has drawn increased attention to its potential use. This review summarizes the effects of L. reuteri on intestinal flora and immune regulation, and discusses the feasibility of its application in atopic dermatitis (AD), asthma, necrotizing enterocolitis (NEC), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and multiple sclerosis (MS), and provides insights for the prevention and treatment of immune-related diseases.

Keywords: Limosilactobacillus reuteri; asthma; atopic dermatitis (AD); immune system disease; multiple sclerosis; necrotizing enterocolitis (NEC); rheumatoid arthritis; systemic lupus erythematosus (SLE).

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Bacterial Agents
Antibodies
Antioxidants
Immunomodulation
Limosilactobacillus reuteri*

Substances

Anti-Bacterial Agents
Antibodies
Antioxidants

Grants and funding

This work was supported by the Jiangsu Provincial Department of Science and Technology (No. BE2022698), the Wuxi Municipal Science and Technology Bureau (No.Y20222003), the Wuxi Municipal Medical Innovation Team (No.CXTD2021013), the Wuxi Commission of Health and Family Planning (Nos. SW202201 and M202171) and the Wuxi Young and Middle-aged Medical Talents Project (No. BJ2020075).